Enlivex Revenue and Competitors
Estimated Revenue & Valuation
- Enlivex's estimated annual revenue is currently $12.5M per year.
- Enlivex's estimated revenue per employee is $201,000
Employee Data
- Enlivex has 62 Employees.
- Enlivex grew their employee count by -15% last year.
Enlivex's People
Name | Title | Email/Phone |
---|
Enlivex Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Enlivex?
Our mission is to establish new equilibriums – both in patients' immune responses and in the field of immunotherapy. As a clinical-stage company focused on specialized cell immunotherapy, we intend to develop and commercialize an allogeneic drug pipeline for rebalancing all manner of immune hyper-responses. Our pioneering Allocetra™ cell-based therapy breaks with old paradigms, offering to effectively treat numerous acute conditions through a radically different clinical approach. By using the body's native mechanisms to restore – rather than suppress – immune balance, we aim to reshape the way immune, autoimmune, and inflammatory conditions are both thought of and treated. Highlights: * Advanced clinical-stage pipeline with promising Phase II results * Short regulatory approval pathway * Multi-billion-dollar markets: Post-BMT complications , Sepsis, Solid tumors
keywords:N/AN/A
Total Funding
62
Number of Employees
$12.5M
Revenue (est)
-15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Enlivex News
Zacks: Brokerages Expect Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Will Post Earnings of -$0.26 Per Share. Posted by admin on Apr 22nd, 2022.
Should Biotechnology Stock Enlivex Therapeutics Ltd (ENLV) Be in Your Portfolio Thursday? The 64 rating InvestorsObserver gives to Enlivex...